TNFRSF17 and Miyoshi myopathy: Prompted by the success of CD19 CAR T-cells, several CAR T-cell therapies are also being developed for MM, among which, major efforts have been devoted to CAR T-cells targeting the B-cell maturation antigen, BCMA (7–11).